Drug Overview: Risperdal Consta

  • ID: 4533520
  • Report
  • 26 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Risperdal Consta (Johnson & Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin (5-HT2), and alpha-2 adrenergic receptors. Risperdal Consta is the long-acting injectable formulation of Johnson & Johnson’s oral drug Risperdal.

Risperdal was initially approved for bipolar disorder in the US in 2003. Johnson & Johnson later launched Risperdal Consta in the US in May 2009. In the following year, EU regulators denied Risperdal Consta approval for the treatment of bipolar disorder, which prompted Johnson & Johnson to abandon the development program in these markets. The drug is also approved for the treatment of schizophrenia.
Note: Product cover images may vary from those shown
2 of 3
OVERVIEW
Drug Overview
Product Profiles
Risperdal Consta: Bipolar disorder
Risperdal Consta: Schizophrenia

List of Figures
Figure 1: Risperdal Consta for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for Risperdal Consta in bipolar disorder
Figure 3: Drug assessment summary for Risperdal Consta in bipolar disorder
Figure 4: Risperdal Consta for schizophrenia - SWOT analysis
Figure 5: Drug assessment summary of Risperdal Consta for schizophrenia
Figure 6: Drug assessment summary of Risperdal Consta for schizophrenia
Figure 7: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Risperdal Consta bipolar disorder indication approvals
Table 2: Risperdal Consta drug profile
Table 3: Risperdal Consta pivotal trial data in bipolar disorder
Table 4: Adverse reactions in =5% of Risperdal Consta-treated adult patients with bipolar disorder
Table 5: Risperdal Consta drug profile
Table 6: Risperdal Consta pivotal trial data in schizophrenia
Table 7: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll